Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.63 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | WIZ | O95785 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.51 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20234982 | 1.00 | CRBN (0.63) | CRBNESR1WIZCSNK1A1IKZF2 | |
| SCHEMBL29799690 | 0.94 | CRBN (0.61) | CRBNESR1WIZCSNK1A1IKZF2 | |
| SCHEMBL26969613 | 0.94 | CRBN (0.61) | CRBNESR1WIZCSNK1A1IKZF2 | |
| SCHEMBL30680844 | 0.94 | CRBN (0.61) | CRBNESR1WIZCSNK1A1IKZF2 | |
| SCHEMBL24697760 | 0.94 | CRBN (0.61) | CRBNESR1WIZCSNK1A1IKZF2 | |
| SCHEMBL25371673 | 0.94 | CRBN (0.61) | CRBNESR1WIZCSNK1A1IKZF2 | |
| SCHEMBL30801298 | 0.94 | CRBN (0.61) | CRBNESR1WIZCSNK1A1IKZF2 | |
| SCHEMBL22581093 | 0.92 | CRBN (0.61) | CRBNESR1WIZCSNK1A1IKZF2 | |
| SCHEMBL29681660 | 0.92 | CRBN (0.61) | CRBNESR1WIZCSNK1A1IKZF2 | |
| SCHEMBL24046445 | 0.92 | CRBN (0.63) | CRBNESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562007-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025103502-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-119923394-A | Targeted protein degradation of PARP14 for use in therapy | 艾伯维新加坡运营私人有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4541795-A1 | AROMATIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF IN PREPARATION OF ESTROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals Inc. (CN) | 2025-04-23 | — | — | EP | disclosed |
| CN-119630644-A | Bifunctional compounds containing pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024259216-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| CN-118955497-A | Imidazo [1,2-a ] pyridine IRAK4 degradation agent and application thereof | 泰诺瑞(天津)生物科技有限责任公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024146502-A1 | WEE1 DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2024-07-11 | — | — | WO | disclosed |
| CN-117836299-A | Novel bifunctional heterocyclic compounds with Bruton tyrosine kinase decomposition via ubiquitin proteasome pathway and uses thereof | 韩国化学研究院 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024026083-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-117229286-A | Aromatic compound, preparation method thereof and application thereof in preparation of estrogen receptor degradation agent | 海创药业股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4240743-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics, Incorporated (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4146655-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BeiGene, Ltd. (KY) | 2023-03-15 | — | — | EP | disclosed |
| CN-115485278-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligands and methods of use thereof | 百济神州有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |